Factor VIIa inhibitors

US6500803B1 · kind B1 · utility

Assignee

• Aventis Pharma Deutschland GmbH · DE

Inventors

• Otmar Klingler · Rodgau, DE
• Manfred Schudok · Eppstein, DE
• Gerhard Zoller · Blankenloch, DE
• Uwe Heinelt · Wiesbaden, DE
• Elisabeth Defossa · Idstein, DE
• Hans Matter · Langenselbold, DE
• Pavel Safar · Tucson, US

Key dates

• Filing date: Jun 7, 2000
• Grant date: Dec 31, 2002
• Expiry date: Jun 7, 2020

Classification

• Technology area (CPC A): Human Necessities
• CPC primary: A61K38/00
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The present invention relates to compounds of formula I, in which R1, R2, R91, R92, R93, R94, R95, R96, R97, r, s, and t have the meanings indicated in the claims. Compounds of formula I are valuable pharmacologically active compounds. They exhibit a strong antithrombotic effect and are suitable, for example, for the therapy and prophylaxis of thromboembolic diseases or restenoses. They are reversible inhibitors of the blood clotting enzyme factor VIIa and can in general be applied in conditions in which an undesired activity of factor VIIa is present or for the cure or prevention of conditions in which an inhibition of factor VIIa is intended. The invention furthermore relates to processes for the preparation of compounds of formula I, their use, in particular as active ingredients in pharmaceuticals, and pharmaceutical preparations comprising them.